Literature DB >> 17338644

Transgenic mouse brains for the evaluation and quality control of BSE tests.

Wolfgang J Philipp1, Darlene Groth, Kurt Giles, Pavel Vodrazka, Heinz Schimmel, Muriel Feyssaguet, Reet Toomik, Pascal Schacher, Awad A Osman, Ingolf Lachmann, Angus Wear, Jean-Noel Arsac, Stanley B Prusiner.   

Abstract

Rapid BSE tests are widely used diagnostics in veterinary medicine and more than 11 million tests are applied worldwide. The evaluation of new rapid BSE tests and the quality assurance of approved BSE tests pose a challenge owing to the natural scarcity of BSE-infected bovine brainstems and regional variations in prion titer. Transgenic mice expressing bovine prion protein (Tg4092) offer an alternative approach to these problems. To determine whether BSE-infected Tg4092 mouse brains could serve as a general standard for rapid BSE tests, we inoculated Tg4092 mice intracerebrally with BSE prions, harvested brains at defined time points post-infection and analyzed cerebral hemispheres with several approved rapid BSE tests. The results show that de novo formation of the disease-causing prion protein isoform, PrP(Sc), can be monitored during the course of infection. We demonstrate that BSE-infected Tg4092 mouse brains provide a renewable and controllable source of reference samples and suggest that such samples can generally be used for the evaluation and quality control of rapid BSE tests.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17338644     DOI: 10.1515/BC.2007.040

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  2 in total

1.  Conformation-dependent high-affinity monoclonal antibodies to prion proteins.

Authors:  Larry H Stanker; Ana V Serban; Elisa Cleveland; Robert Hnasko; Azucena Lemus; Jiri Safar; Stephen J DeArmond; Stanley B Prusiner
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

2.  Resistance of bovine spongiform encephalopathy (BSE) prions to inactivation.

Authors:  Kurt Giles; David V Glidden; Robyn Beckwith; Rose Seoanes; David Peretz; Stephen J DeArmond; Stanley B Prusiner
Journal:  PLoS Pathog       Date:  2008-11-14       Impact factor: 6.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.